Guardant Health, Inc. CEO Helmy Eltoukhy described the recent US Food and Drug Administration approval of the company’s liquid biopsy test Guardant360 CDx as a “watershed moment for comprehensive liquid biopsy” because it provides oncologists with the information they need to close the gap between clinical guidelines and clinical practice.
The Redwood City, CA-based liquid biopsy company announced on 7 August that its Guardant360 assay was approved for comprehensive tumor...




